Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Aquestive Therapeutics has a consensus “Buy” rating from seven analysts, with four Buy, two Strong Buy and one Sell rating; the average 12-month price target is $8.50 versus a recent share price of $4.23.
• Second-quarter revenue of $13.82 million exceeded expectations of $11.42 million, but the company reported a larger-than-expected loss of $0.18 per share compared with the $0.10 consensus estimate.
• Full-year 2026 revenue guidance of $46 million–$50 million is below the roughly $50.8 million analyst consensus, while investors continue to monitor regulatory progress and commercialization of Aquestive’s product pipeline.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received an average rating of "Buy" from the seven brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.50.

Several equities research analysts have recently commented on AQST shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 16th. Finally, Oppenheimer started coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They set an "outperform" rating and a $8.00 price target on the stock.

Insider Activity

In related news, CEO Daniel Barber sold 8,257 shares of the firm's stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $4.29, for a total value of $35,422.53. Following the completion of the sale, the chief executive officer directly owned 660,574 shares in the company, valued at approximately $2,833,862.46. This trade represents a 1.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julie Krop sold 25,000 shares of Aquestive Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the transaction, the director owned 25,000 shares of the company's stock, valued at $125,500. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by insiders.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AQST. Elevation Point Wealth Partners LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $42,000. Quantbot Technologies LP bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $99,000. Bratton Capital Management L.P. acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $40,813,585,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $52,000. Finally, Blue Owl Capital Holdings LP bought a new stake in Aquestive Therapeutics in the 2nd quarter valued at $3,923,000. Institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Trading Down 4.1%

Shares of AQST opened at $4.23 on Thursday. Aquestive Therapeutics has a 12 month low of $2.93 and a 12 month high of $7.55. The firm has a fifty day simple moving average of $4.13 and a 200 day simple moving average of $4.07. The stock has a market capitalization of $530.74 million, a price-to-earnings ratio of -6.51 and a beta of 1.49.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to analysts' expectations of $11.42 million. As a group, research analysts predict that Aquestive Therapeutics will post -0.41 earnings per share for the current fiscal year.

Aquestive Therapeutics News Roundup

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Second-quarter revenue rose to $13.82 million, exceeding the $11.42 million analyst consensus. Management also provided a business update focused on advancing its product pipeline and preparations for future commercialization. Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The earnings call and related coverage kept attention on Aquestive’s regulatory progress and commercial preparation. Any advancement toward approval and launch of its lead products could provide a longer-term catalyst for AQST, although investors still appear focused on execution and timing. Aquestive Therapeutics Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Reports describing a sharp increase in short interest appear unreliable: the data show zero shares short both currently and previously, with a zero-day days-to-cover ratio. This provides no meaningful indication of additional short-selling pressure.
• Negative Sentiment: Aquestive reported a second-quarter loss of $0.18 per share, wider than the expected $0.10 loss and the $0.14 loss recorded a year earlier. The earnings miss suggests that expenses and investment in development or commercialization remain elevated. Aquestive Therapeutics Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Full-year 2026 revenue guidance of $46 million to $50 million is below the approximately $50.8 million consensus estimate. The lower outlook, combined with the earnings miss, likely overshadowed the quarterly revenue beat. Aquestive Therapeutics Q2 Loss Widens, Revenue Rises

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source